Endonovo Therapeutics, Inc.
ENDV
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -4.40M | -4.24M | -8.83M | -18.47M | -3.15M |
| Total Depreciation and Amortization | 646.80K | 646.80K | 646.80K | 646.80K | 646.80K |
| Total Amortization of Deferred Charges | 32.30K | 66.20K | 83.90K | 110.70K | 131.00K |
| Total Other Non-Cash Items | 1.53M | 1.02M | 5.41M | 15.03M | -236.80K |
| Change in Net Operating Assets | 1.57M | 1.82M | 1.96M | 2.01M | 1.76M |
| Cash from Operations | -629.90K | -688.40K | -729.10K | -678.90K | -844.70K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 260.00K | 361.00K | 365.00K | 465.00K | 875.00K |
| Total Debt Repaid | -52.00K | -35.00K | -34.00K | -14.00K | -13.00K |
| Issuance of Common Stock | 398.80K | 395.00K | 349.00K | 142.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 606.80K | 721.00K | 680.00K | 593.00K | 862.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.10K | 32.60K | -49.10K | -85.90K | 17.30K |